Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | PRKACA | P17612 | 3/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.55 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.55 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.55 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056654 | 0.84 | CHRNB2 (0.70) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL8675780 | 0.84 | MKNK2 (0.55) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL4959044 | 0.84 | MKNK2 (0.55) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL6660327 | 0.83 | CHRNB2 (0.63) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL4064436 | 0.81 | CHRNB2 (0.74) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL6662274 | 0.79 | CHRNB2 (0.43) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL6667220 | 0.78 | CYP11B2 (0.40) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL3017868 | 0.78 | CHRNB2 (0.53) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL3017873 | 0.78 | CHRNB2 (0.53) | MKNK2ROCK2MAP4K4PRKACAROCK1 | |
| SCHEMBL7071081 | 0.76 | ROCK2 (0.50) | MKNK2ROCK2MAP4K4PRKACAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0900200-B9 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-10-21 | — | — | EP | disclosed |
| EP-1997806-A1 | Pahrmaceutical compositions for prevention and treatment of central nervous system disorders | Targacept, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-0900200-B1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-6603011-B1 | Representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine; the prevention and treatment of CNS disorders which have been attributed to neurotransmitter system dysfunction | TARGACEPT, INC. | 2003-08-05 | — | — | US | disclosed |
| US-6555684-B2 | A pyridine or pyrimidine derivatives containing primary, secondary or tertiary amine group | TARGACEPT, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | CALDWELL WILLIAM SCOTT (US) | 2002-03-14 | — | — | US | disclosed |
| EP-0900200-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040011-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTION AND TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | R. J. REYNOLDS TOBACCO COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5616716-A | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds | TARGACEPT, INC. | 1997-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032206-A1 | Pharmaceutical compositions for prevention and treatment of central nervous system disorders | PMP22, AANAT, CHAT | MKNK2 2535/4885ROCK2 4523/4885MAP4K4 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.